Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 319 participants.
Also called NCT01752985
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 319 participants
- Sponsor
- Registry
-
NCT01752985 -
2012-005093-54
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Denmark, France
- Registry status
- Terminated
Technical summary
Registry record NCT01752985. Randomized; double masking; primary purpose treatment. Start 2013-03-18 (actual); primary completion 2015-06-30 (actual). Results posted on 2019-06-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
- Condition
- Diabetic Kidney Disease
- Intervention (Drug)
- BMS-813160
- Intervention (Drug)
- Placebo matching with BMS-813160
- Lead sponsor
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct01752985- Content hash
d48ad3c95233389571a5da275deae6ec8605889fa6780260d143bae2dc9d4389